Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at Ned Davis Research from a “sell” rating to a “neutral” rating in a research note issued to investors on Monday.Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares after opening at $282.80 moved to $300.20 on last trade day and at the end of the day closed at $299.58. Company price to sales ratio in past twelve months was calculated as 14.36 and price to cash ratio as 43.55. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) showed a negative weekly performance of -3.88%.
April 24, 2014 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the first quarter of 2014 on Thursday, May 8, 2014, before the market opens. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares advanced 10.58% in last trading session and ended the day on $14.00. VNDA return on equity ratio is recorded as -76.90% and its return on assets is -15.00%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) yearly performance is 189.86%.
Analysts at Brinson Patrick started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report issued to clients and investors on Monday. The firm set an “outperform” rating and a $15.00 price target on the stock. Brinson Patrick’s price target points to a potential upside of 80.07% from the company’s current price. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved up 8.93% in last trading session and was closed at $8.42, while trading in range of $7.68-$8.51. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) year to date performance is 10.79%.
Novavax, Inc. (Nasdaq: NVAX) announced positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in women of childbearing age. The randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety of multiple formulations of Novavax’ RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate. Novavax, Inc. (NASDAQ:NVAX) weekly performance is 4.18%. On last trading day company shares ended up $4.49. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average is -9.81%. Analysts mean target price for the company is $11.20.